J Korean Ophthalmol Soc > Volume 53(2); 2012 > Article
Journal of the Korean Ophthalmological Society 2012;53(2):283-290.
DOI: https://doi.org/10.3341/jkos.2012.53.2.283    Published online February 15, 2012.
Long-Term Effects of Intravitreal Bevacizumab Injection for Macular Edema Secondary to Branch Retinal Vein Occlusion.
In Je Song, Hyun Woong Kim, Il Han Yun
Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. maekbak@hanmail.net
망막분지정맥폐쇄에 의한 황반부종에서 유리체강내 베바시주맙 주입술의 장기효과
Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
To report the long term effects of intravitreal bevacizumab injection (IVAI) for the treatment of macular edema due to branch retinal vein occlusion (BRVO). METHODS: In this retrospective study, 47 consecutive patients (47 eyes) whose visual acuity under 20/40 and macular thickness over 250 microm from BRVO received IVAI (1.25 mg). All patients were observed over 12 months. The patients were classified into three groups: one, resolved macular edema after first injection, second, persistant, third, recurrant. At 12 months after injection, best corrected visual acuity (BCVA) and central macular thickness (CMT) were compared with one another. RESULTS: Comparing with baseline BCVA (0.96 +/- 0.32, 1.13 +/- 0.42, 0.85 +/- 0.24 log MAR unit), the mean at 12 months was significantly increased (0.50 +/- 0.30, 0.76 +/- 0.51, 0.55 +/- 0.35) in each group. The mean CMT at baseline was 510.84 (+/- 171.07), 538.5 (+/- 216.87), 522.6 (+/- 101.82) microm decreased to 211.58 (+/- 42.74), 232 (+/- 132.68), 270.6 (+/- 85.27). CONCLUSIONS: IVAI was a result of significant decrease of CMT with improvement of BCVA in patients with BRVO after a follow-up of 12 months.
Key Words: Bevacizumab;Branch retinal vein occlusion;Intravitreal injection;Macular edema

Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next